First Cases of Allergic Contact Dermatitis From the New FreeStyle Libre 3 Sensor: Small Device, Multiple Allergens

Silada Kanokrungsee, Ella Dendooven, Kenn Foubert, Tania Naessens, Emmy Tuenter, Nina Hermans, Olivier Aerts
Contact Dermatitis · Wiley · 2026-11-18 · DOI: 10.1111/cod.70287

Abstract

ABSTRACT Background Allergic contact dermatitis (ACD) from glucose sensors has become increasingly common. Newer devices, such as FreeStyle Libre 3 (Abbott Diabetes Care, UK), have been developed to enhance performance and reduce skin reactions. No ACD cases linked to this particular device have been reported to date. Objective To document the first cases of ACD linked to the FreeStyle Libre 3 sensor and to identify potential culprit allergenic components through patch testing and chemical analyses. Methods A retrospective chart review was conducted on 15 patients with suspected ACD related to the FreeStyle Libre 3 device who underwent patch testing at Antwerp University Hospital between November 2023 and November 2025. Chemical analyses of the device and associated adhesive components were performed using gas chromatography–mass spectrometry (GC–MS). Results Ten patients (67%) were diagnosed with ACD and most had prior exposure to other glucose sensors. The most frequent allergens were colophonium and related compounds, followed by (meth)acrylates, isocyanates and tert‐butylphenol (TBP) derivatives. GC–MS analyses revealed the presence of most of these chemicals. Conclusions Multiple newly identified as well as (modified) classic sensitizers contribute to ACD from the FreeStyle Libre 3 glucose sensor. Comprehensive ingredient disclosure and extended patch testing are essential for accurate diagnosis and prevention.

Read at publisher →

Similar articles